Last reviewed · How we verify
anti-pseudomonal cephalosporin
anti-pseudomonal cephalosporin is a Anti-pseudomonal cephalosporin Small molecule drug developed by Vanderbilt University Medical Center. It is currently FDA-approved for Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream), Gram-negative aerobic bacterial infections in hospitalized patients.
Anti-pseudomonal cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall disruption and bacterial death.
Anti-pseudomonal cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall disruption and bacterial death. Used for Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream), Gram-negative aerobic bacterial infections in hospitalized patients.
At a glance
| Generic name | anti-pseudomonal cephalosporin |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Anti-pseudomonal cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These are beta-lactam antibiotics that target gram-negative bacteria, particularly Pseudomonas aeruginosa, which are resistant to earlier-generation cephalosporins. They penetrate the outer membrane of gram-negative organisms and covalently bind to penicillin-binding proteins, preventing cross-linking of peptidoglycan and causing bactericidal cell lysis.
Approved indications
- Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream)
- Gram-negative aerobic bacterial infections in hospitalized patients
Common side effects
- Diarrhea
- Nausea
- Hypersensitivity reactions
- Phlebitis at injection site
- Elevated liver enzymes
Key clinical trials
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Effect of Antibiotic Choice On ReNal Outcomes (ACORN) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-pseudomonal cephalosporin CI brief — competitive landscape report
- anti-pseudomonal cephalosporin updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI
Frequently asked questions about anti-pseudomonal cephalosporin
What is anti-pseudomonal cephalosporin?
How does anti-pseudomonal cephalosporin work?
What is anti-pseudomonal cephalosporin used for?
Who makes anti-pseudomonal cephalosporin?
What drug class is anti-pseudomonal cephalosporin in?
What development phase is anti-pseudomonal cephalosporin in?
What are the side effects of anti-pseudomonal cephalosporin?
What does anti-pseudomonal cephalosporin target?
Related
- Drug class: All Anti-pseudomonal cephalosporin drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs)
- Manufacturer: Vanderbilt University Medical Center — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream)
- Indication: Drugs for Gram-negative aerobic bacterial infections in hospitalized patients
- Compare: anti-pseudomonal cephalosporin vs similar drugs
- Pricing: anti-pseudomonal cephalosporin cost, discount & access